News from alligator bioscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

07 Apr, 2020, 08:28 BST Alligator Bioscience Increases Focus on Clinical Development

Alligator Bioscience (Nasdaq Stockholm: ATORX) , announced today that the company has decided to increase its focus on the clinical development...


01 Apr, 2020, 09:32 BST Alligator Bioscience Informs About Temporary Halt of Recruitment of New Patients due to the COVID-19 Pandemic

Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new patients to the company's ongoing Phase I...


31 Mar, 2020, 08:52 BST Notice of Annual General Meeting in Alligator Bioscience AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text...


05 Mar, 2020, 13:03 GMT Alligator Bioscience Appoints Andreas Johannesson as interim Chief Financial Officer

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The...


02 Mar, 2020, 09:42 GMT Alligator Bioscience's Annual Report 2019 Published

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


12 Feb, 2020, 07:23 GMT Alligator Bioscience AB Year-end Report January-December 2019

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at...


17 Dec, 2019, 12:13 GMT Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the...


29 Nov, 2019, 07:45 GMT Alligator Bioscience AB Appoints Chief Operating Officer

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Malin Carlsson as Chief Operating Officer. She most...


08 Nov, 2019, 14:13 GMT Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and...


06 Nov, 2019, 13:17 GMT Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity - New Preclinical Data to be Presented at SITC 34th Annual Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinical data showing that their drug candidate...


24 Oct, 2019, 07:26 BST Alligator Bioscience AB Interim Report January-September 2019

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to,...


20 Aug, 2019, 15:57 BST Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. ("Biotheus"), a...


31 Jul, 2019, 07:08 BST Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop ...


11 Jul, 2019, 07:36 BST Alligator Bioscience AB (publ) Interim Report January-June 2019

Significant events April-June Janssen presented data from the clinical Phase I study with ADC-1013 indicates good safety and shows initial signs of...


18 Jun, 2019, 15:26 BST Alligator Bioscience Submits Clinical Trial Application for ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


16 May, 2019, 07:45 BST Alligator Bioscience to Present the ATOR-1015 Phase I Study Outline at ASCO

Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announces that the outline of the ongoing Phase I study with the bispecific drug candidate...


16 May, 2019, 00:29 BST Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study...


17 Apr, 2019, 07:43 BST The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bioscience has presented its proposal for...


17 Apr, 2019, 07:29 BST Alligator Bioscience AB (publ) Interim Report January-March 2019

Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong...


10 Apr, 2019, 09:53 BST Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Chief Medical Officer Charlotte Russell, MD, PhD, will give an oral presentation ...


02 Apr, 2019, 12:42 BST Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the...


22 Mar, 2019, 08:42 GMT Alligator Bioscience's Annual Report 2018 Published

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


18 Mar, 2019, 12:50 GMT Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th...


07 Mar, 2019, 11:11 GMT Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the first patient has successfully been dosed in its phase I study of ATOR-1015,...


14 Feb, 2019, 07:58 GMT Alligator Bioscience AB Year-end Report 2018

Significant events October-December The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New preclinical...